Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru
- Mezones-Holguín, Edward
- Canelo Aybara, Carlos
- David Clark, Andrew
- Bess Janusz, Cara
- Jaúregui, Bárbara
- Escobedo Palza, Seimer
- Hernandez, Adrian V.
- Berhane, Yemane
- Vega Porras, Denhiking
- González, Marco
- Fiestas, Fabián
- Toledo , Washington
- Michele, Fabiana
- Suárez, Víctor J.
DOIAbstract
Objective To evaluate the cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine (PCV10) versus the 13-valent PCV (PCV13) to the National Immunization Schedule in Peru for prevention of pneumococcal disease (PD) in children <5 years of age. Methods The integrated TRIVAC vaccine cost-effectiveness model from the Pan American Health Organization's ProVac Initiative (version 2.0) was applied from the perspective of the Government of Peru. Twenty successive cohorts of children from birth to 5 years were evaluated. Clinical outcomes were pneumococcal pneumonia (PP), pneumococcal meningitis (PM), pneumococcal sepsis (PS) and acute otitis media from any causes (AOM). Measures included prevention of cases, neurological seque...
Add to ORKG